Onconova Therapeutics, Inc. (ONTX)
ONTXPrice: $1
Fair Value: 🔒
🔒score
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well ... more
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and ... more
Description
Shares
| Market Cap | $20.90M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Steven M. Fruchtman |
| IPO Date | 2013-07-25 | CAGR | -0.13% |
| Employees | 16 | Website | www.onconova.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ONTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $25.34M | P/E Ratio | -1.04 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 3.2 | P/B Ratio | 1.37 |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-0.96 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 97.47% | Gross Margin | 1% |
| Operating Margin | -15.4% | Profit Margin | 30.18% |
| ROE | -18.07% | ROA | 5.61% |
| ROCE | -5.41% | Current Ratio | 2.09 |
| Quick Ratio | 2.09 | Cash Ratio | 1.78 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | -56.25 | Piotroski Score | 4 |